These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 2008193)

  • 1. The Medicare end-stage renal disease program. A report from the Institute of Medicine.
    Levinsky NG; Rettig RA
    N Engl J Med; 1991 Apr; 324(16):1143-8. PubMed ID: 2008193
    [No Abstract]   [Full Text] [Related]  

  • 2. Toward Antiracist Reimbursement Policy in End-Stage Kidney Disease: From Equality to Equity.
    Taylor K; Crews DC
    J Am Soc Nephrol; 2021 Oct; 32(10):2422-2424. PubMed ID: 34253586
    [No Abstract]   [Full Text] [Related]  

  • 3. Quality and equity in dialysis and renal transplantation.
    Levinsky NG
    N Engl J Med; 1999 Nov; 341(22):1691-3. PubMed ID: 10572161
    [No Abstract]   [Full Text] [Related]  

  • 4. The American health care system. The End Stage Renal Disease Program.
    Iglehart JK
    N Engl J Med; 1993 Feb; 328(5):366-71. PubMed ID: 8419833
    [No Abstract]   [Full Text] [Related]  

  • 5. Extension of Medicare immunosuppressive drug benefits: a "no brainer" that did not happen.
    Bennett WM
    Clin J Am Soc Nephrol; 2010 May; 5(5):743. PubMed ID: 20448072
    [No Abstract]   [Full Text] [Related]  

  • 6. End stage renal disease and Medicare.
    Greer JW
    Health Care Financ Rev; 2003; 24(4):1-5. PubMed ID: 14628396
    [No Abstract]   [Full Text] [Related]  

  • 7. Providers skittish about Medicare kidney-care ACO initiative.
    Rice S
    Mod Healthc; 2014 Sep; 44(35):10. PubMed ID: 25318272
    [No Abstract]   [Full Text] [Related]  

  • 8. Disparities among Blacks, Hispanics, and Whites in time from starting dialysis to kidney transplant waitlisting.
    Joshi S; Gaynor JJ; Bayers S; Guerra G; Eldefrawy A; Chediak Z; Companioni L; Sageshima J; Chen L; Kupin W; Roth D; Mattiazzi A; Burke GW; Ciancio G
    Transplantation; 2013 Jan; 95(2):309-18. PubMed ID: 23325005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare program; end-stage renal disease quality incentive program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2011 Jan; 76(3):627-46. PubMed ID: 21261127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. X. The economic cost of ESRD and Medicare spending for alternative modalities of treatment.
    Am J Kidney Dis; 1999 Aug; 34(2 Suppl 1):S124-39. PubMed ID: 10431009
    [No Abstract]   [Full Text] [Related]  

  • 11. The Medicare cost of renal dialysis. Evidence from a statistical cost function.
    Dor A; Held PJ; Pauly MV
    Med Care; 1992 Oct; 30(10):879-91. PubMed ID: 1405794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare Program; End-Stage Renal Disease Prospective Payment System, Coverage and Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program Bid Surety Bonds, State Licensure and Appeals Process for Breach of Contract Actions, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program and Fee Schedule Adjustments, Access to Care Issues for Durable Medical Equipment; and the Comprehensive End-Stage Renal Disease Care Model. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2016 Nov; 81(214):77834-969. PubMed ID: 27905888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Must health literacy be a prerequisite for kidney transplantation?
    Gaston RS
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):16-7. PubMed ID: 19129316
    [No Abstract]   [Full Text] [Related]  

  • 14. How dialysis is paid for: what the dialysis medical director should know, and why.
    Deoreo PB
    Semin Dial; 2008; 21(1):58-62. PubMed ID: 18086259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare Program; Conditions for Coverage for End-Stage Renal Disease Facilities--Third Party Payment. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2016 Dec; 81(240):90211-28. PubMed ID: 28001019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The direction of end-stage renal disease reimbursement in the United States.
    Lockridge RS
    Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding financial risk models: Implicationsfor nephrology practices and dialysis centers.
    Cellini GL
    Nephrol News Issues; 2016 Mar; 30(3):26-8, 30-3. PubMed ID: 27169216
    [No Abstract]   [Full Text] [Related]  

  • 18. The economics of kidney transplantation versus hemodialysis.
    Loubeau PR; Loubeau JM; Jantzen R
    Prog Transplant; 2001 Dec; 11(4):291-7. PubMed ID: 11871278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, and End-Stage Renal Disease Quality Incentive Program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2017 Nov; 82(210):50738-97. PubMed ID: 29091373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible effects of the new Medicare reimbursement policy on African Americans with ESRD.
    Ishani A; Guo H; Arneson TJ; Gilbertson DT; Mau LW; Li S; Dunning S; Collins AJ
    J Am Soc Nephrol; 2009 Jul; 20(7):1607-13. PubMed ID: 19389846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.